000K utf8 1100 $c2022 1500 eng 2050 urn:nbn:de:gbv:8:3-2022-00501-3 2051 10.3389/fimmu.2022.932155 3000 Chan, Chilam 3010 Baumann, Niklas 3010 Leusen, Jeanette H. W. 3010 Lustig, Marta 3010 Valerius, Thomas 3010 van Tetering, Geert 4000 Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy$dA Novel Anti-Cancer Strategy With IgA Antibodies? [Chan, Chilam] 4209 Immunotherapy with therapeutic antibodies has shown a lack of durable responses in some patients due to resistance mechanisms. Checkpoint molecules expressed by tumor cells have a deleterious impact on clinical responses to therapeutic antibodies. Myeloid checkpoints, which negatively regulate macrophage and neutrophil anti-tumor responses, are a novel type of checkpoint molecule. Myeloid checkpoint inhibition is currently being studied in combination with IgG-based immunotherapy. In contrast, the combination with IgA-based treatment has received minimal attention. IgA antibodies have been demonstrated to more effectively attract and activate neutrophils than their IgG counterparts. Therefore, myeloid checkpoint inhibition could be an interesting addition to IgA treatment and has the potential to significantly enhance IgA therapy. 4950 https://doi.org/10.3389/fimmu.2022.932155$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2022-00501-3$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/macau_mods_00002913 5051 610 5550 Antibodies 5550 Antigens, Differentiation 5550 Cancer Immonotherapy 5550 CD47 Antigen 5550 Cd47-sirpalpha Axis 5550 Humans 5550 IGA 5550 Immune Checkpoint 5550 Immunoglobulin A 5550 Immunoglobulin G 5550 Macrophages 5550 Myeloid Checkpoints 5550 Neoplasms 5550 Neutrophils (Pmns) 5550 Phagocytosis 5550 Receptors, Immunologic